Cantargia AB (publ) (STO:CANTA)

Market Cap	625.26M
Revenue (ttm)	n/a
Net Income (ttm)	-167.61M
Shares Out	248.61M
EPS (ttm)	-0.78
PE Ratio	n/a
Forward PE	4.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,781,024
Average Volume	1,588,742
Open	2.620
Previous Close	2.600
Day's Range	2.515 - 2.640
52-Week Range	1.000 - 4.780
Beta	1.59
RSI	41.74
Earnings Date	Nov 19, 2025

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CANTA